Price$13.54+1.88 (+16.12%)
01:30 PM07:45 PM
News · 26 weeks67+50%
2026-01-182026-07-12
Mix4490d
- SEC Filings18(41%)
- Other15(34%)
- Insider7(16%)
- Earnings2(5%)
- Analyst1(2%)
- Leadership1(2%)
Latest news
25 items- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD Anderson team, led by Dr. Samuels, has also treated multiple patients - - Immunocompromised patients face dramatically higher rates of cSCC, the second most common type of skin cancer in the U.S., than the general population - as much as 65- to 100-fold among organ transplant recipients specifically - - For many patients in this population, the general treatment options for recurrent cSCC can actually cause real harm: checkpoint inhibitor immunotherapy, the standard option for the g
- INSIDERChief Financial Officer Levy Raphi sold $31,782 worth of Ordinary Shares (2,270 units at $14.00) and exercised 2,270 units of Ordinary Shares at a strike of $2.98 (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- INSIDERChief Financial Officer Levy Raphi exercised 17,873 units of Ordinary Shares at a strike of $2.98 and sold $232,397 worth of Ordinary Shares (17,873 units at $13.00) (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- INSIDERChief Financial Officer Levy Raphi exercised 2,127 units of Ordinary Shares at a strike of $2.98 and sold $27,691 worth of Ordinary Shares (2,127 units at $13.02) (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- INSIDERChief Financial Officer Levy Raphi sold $240,044 worth of Ordinary Shares (20,000 units at $12.00), decreasing direct ownership by 18% to 90,180 units (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- INSIDERChief Financial Officer Levy Raphi sold $220,004 worth of Ordinary Shares (20,000 units at $11.00), decreasing direct ownership by 15% to 110,180 units (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PROramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetSignificant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa
- INSIDERChief Financial Officer Levy Raphi sold $167,051 worth of Ordinary Shares (17,500 units at $9.55), decreasing direct ownership by 12% to 130,180 units (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel- First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah University Medical Center in Jerusalem, one of the world’s premier academic neurosurgical institutions - - The procedure marks the first international clinical application of Alpha DaRT’s brain-specific proprietary delivery system - - Glioblastoma is the most common and aggressive primary brain cancer, with approximately 160,000 new cases diagnosed globally each year; with recurrence occurring in virtually all patients, typically within 6-9 months, for which there is no established standard of care - - The patient was treated under the ALL clinical proto
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining seven patients in the trial - - Marks the latest in a series of regulatory successes in this indication, following FDA's recognition of Alpha DaRT's potential through its Breakthrough Device Designation for recurrent glioblastoma (GBM) and Alpha Tau's selection for the FDA's prestigious Total Product Life Cycle (TPLC) Advisory Program (TAP) - - With approximately 14,000 Americans newly diagnosed with glioblastoma each year and median survival after recurrence typically measured in months, Alpha D
- INSIDERChief Financial Officer Levy Raphi sold $352,115 worth of Ordinary Shares (32,500 units at $10.83), decreasing direct ownership by 18% to 147,680 units (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients- Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates prostate cancer as a core strategic focus, backed by Tolmar's initial $15M manufacturing investment, $20M equity infusion at $11.99 per share (25% premium to 30-day VWAP), and up to $161.5M in clinical, regulatory and commercial milestones for the first indication - Agreement grants Tolmar exclusive U.S. commercialization rights for prostate cancer, with an option to expand into bladder cancer subject to additional payments - Alpha Tau to manufacture Alpha DaRT for Tolmar's commercialization,
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of three prospective Phase I/II studies in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates encouraging median overall survival (mOS) across chemotherapy-naive, second-line, and heavily pretreated patient populations - - Patients treated with Alpha DaRT after 1st line chemotherapy reached median overall survival (mOS) of 11.2 and 11.1 months in metastatic and locally advanced disease, respectively, from the date of trial enrollment, compared to ~4 - 6 months for met
- ANALYSTBarclays initiated coverage on Alpha Tau with a new price targetBarclays initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $15.00
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company's first U.S. pivotal study - - Pooled data from two pancreatic cancer trials presented at Digestive Disease Week (DDW) 2026 demonstrated 100% local disease control and favorable safety, the first oral presentation of Alpha DaRT® pancreatic data at a premier international gastroenterology conference - - Abstracts accepted for presentation at the 2026 ASCO Annual Meeting and at th
- PRAlpha Tau to Participate in May Investor ConferencesJERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in May 2026. Event:H.C. Wainwright 4th Annual BioConnect Investor ConferenceFormat:Fireside Chat and 1x1 MeetingsDate:Tuesday, May 19, 2026Time:10:30 – 11:00AM ETLocation:New York, NY Event:Rothschild & Co Redburn Radiopharma Conference 2026Format:1x1 MeetingsDate:Wednesday, May 27, 2026Location:New York, NY Event:Lytham Partners Spring 2026 Investor ConferenceFormat:Presentation and 1x1 MeetingsDate:Thu
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
DRTS FAQ
6 questionsWhat does Alpha Tau Medical Ltd. do?
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Where does DRTS stock trade?
Alpha Tau Medical Ltd. (DRTS) is listed on NASDAQ.What sector and industry is DRTS in?
Alpha Tau Medical Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about DRTS?
Alpha Tau Medical Ltd. has had 7 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $1500.00 price target on 2026-05-28. Recent price targets range from $500.00 to $2100.00.What companies are similar to DRTS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare DRTS side-by-side with any of them on Quantisnow.How can I track DRTS on Quantisnow?
Quantisnow aggregates Alpha Tau Medical Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DRTS to receive live email and push alerts on every new disclosure.